ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 7, 2021

9:30AM-9:45AM: Abstract Number: 0950

Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis/Racemosa

Abstracts: Antiphospholipid Syndrome (0948–0951)

9:30AM-9:45AM: Abstract Number: 0954

The Association of Rituximab- vs. Cyclophosphamide-Based Remission Induction Strategies with Risk of End-Stage Renal Disease and Death in ANCA-Associated Vasculitis

Abstracts: Vasculitis – ANCA-Associated (0952–0955)

9:30AM-9:45AM: Abstract Number: 0942

Transcriptional Regulation of Synovial Macrophages in the Aging Joint

Abstracts: Osteoarthritis & Joint Biology – Basic Science (0940–0943)

9:45AM-10:00AM: Abstract Number: 0951

Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

Abstracts: Antiphospholipid Syndrome (0948–0951)

9:45AM-10:00AM: Abstract Number: 0947

Cytokine Competent Gut-joint Migratory T Cells Contribute to Inflammation in the Joint

Abstracts: Spondyloarthritis Including PsA – Basic Science (0944–0947)

9:45AM-10:00AM: Abstract Number: 0943

Metabolomic Profiling of Synovial Tissue of Patients with Osteoarthritis

Abstracts: Osteoarthritis & Joint Biology – Basic Science (0940–0943)

9:45AM-10:00AM: Abstract Number: 0955

The Effect of Treatment with the Complement C5a Receptor Inhibitor Avacopan on Health-Related Quality of Life in ANCA-Associated Vasculitis

Abstracts: Vasculitis – ANCA-Associated (0952–0955)

10:30AM-10:45AM: Abstract Number: 0962

Association of Antiphospholipid Antibodies with Thromboembolic Events and Severe Outcomes in COVID-19

Abstracts: Infection-related Rheumatic Disease (0962–0965)

10:30AM-10:45AM: Abstract Number: 0966

Integrated Single Cell RNA-Sequencing Analysis of Tissue-Localized T Cells in Cutaneous Lupus and Lupus Nephritis

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (0966–0969)

10:30AM-10:45AM: Abstract Number: 0956

Racial Disparities in Renal Outcomes over Time Among Hospitalized Children with SLE and Effects of Hospital Minority Composition

Plenary II (0956–0961)

10:45AM-11:00AM: Abstract Number: 0967

Antigen-specific and Bystander Autoreactive T Cell Control in Peripheral Blood of ACPA+ Rheumatoid Arthritis Patients Administered Antigen-specific Tolerising Immunotherapy

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (0966–0969)

10:45AM-11:00AM: Abstract Number: 0963

Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRDs)

Abstracts: Infection-related Rheumatic Disease (0962–0965)

10:45AM-11:00AM: Abstract Number: 0957

Vitamin D and Marine n-3 Fatty Acid Supplementation and Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial

Plenary II (0956–0961)

11:00AM-11:15AM: Abstract Number: 0968

Granzyme K+ CD8 T Cells Form the Core Population of Inflamed Human Tissue-associated CD8 T Cells

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (0966–0969)

11:00AM-11:15AM: Abstract Number: 0958

Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors

Plenary II (0956–0961)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].